ADMA Biologics
ADMA
88 hedge funds and large institutions have $137M invested in ADMA Biologics in 2021 Q4 according to their latest regulatory filings, with 31 funds opening new positions, 23 increasing their positions, 21 reducing their positions, and 14 closing their positions.
190% more capital invested
Capital invested by funds: $47.3M → $137M (+$89.8M)
121% more first-time investments, than exits
New positions opened: 31 | Existing positions closed: 14
22% more funds holding
Funds holding: 72 → 88 (+16)
17.05% more ownership
Funds ownership: 32.6% → 49.65% (+17%)
10% more repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 21
70% less call options, than puts
Call options by funds: $632K | Put options by funds: $2.12M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$13M |
| 2 |
MF
Magnetar Financial
Evanston,
Illinois
|
+$8.31M |
| 3 |
CC
Clearline Capital
New York
|
+$7.37M |
| 4 |
BFM
Boothbay Fund Management
New York
|
+$6.77M |
| 5 |
AIC
AWM Investment Company
New York
|
+$6.02M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
-$1.75M |
| 2 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$669K |
| 3 |
Millennium Management
New York
|
-$542K |
| 4 |
Morgan Stanley
New York
|
-$432K |
| 5 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$329K |
ADMA Hedge Fund Activity: Q4 2021 in Review
88 of the 6,518 institutional investors tracked by Wall St. Rank reported a position in ADMA Biologics (ADMA) for Q4 2021, worth a combined $137M — up 190% from $47.3M a quarter earlier.
Buyers outnumbered sellers: 31 funds opened new ADMA positions and 14 closed out — a net gain of 17 holders — while 23 added to existing stakes and 21 trimmed.
The largest buyer was Stonepine Capital Management, opening a new position worth an estimated $13M. The largest seller was Perceptive Advisors, cutting an estimated $1.75M.
- 88 institutional investors held ADMA Biologics (ADMA) as of Q4 2021, up from 72 in Q3 2021.
- Funds reported $137M of ADMA Biologics stock for Q4 2021, up 190% quarter-over-quarter.
- 31 funds opened new ADMA Biologics positions in Q4 2021 and 14 closed out, a net change of +17 holders.
- The largest ADMA Biologics buyer in Q4 2021 was Stonepine Capital Management, an estimated $13M added.
- The largest ADMA Biologics seller in Q4 2021 was Perceptive Advisors, an estimated $1.75M sold.
Based on aggregated 13F filings for Q4 2021.